Colorectal cancer progression: Integrin αvβ6 and the epithelial-mesenchymal transition (EMT)

Cell Cycle

Volumn 4, Issue 10, 2005, Pages 1350-1352

  Bates, Richard C ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Colon cancer; Cytokines; Epithelial mesenchymal transition; Integrins; Tumor progression

Indexed keywords

CD51 ANTIGEN;

CARCINOGENESIS; CELL FUNCTION; COLORECTAL CARCINOMA; EPITHELIUM CELL; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; MORTALITY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SHORT SURVEY;

EID: 26444466006     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.10.2053     Document Type: Short Survey

References (35)

1. Markowitz SD, Dawson DM, Willis J, Willson JKV. Focus on colon cancer. Cancer Cell 2002; 1:233-6.
2. McDermott U, Longley DB, Johnston PG. Molecular and biochemical markers in colorectal cancer. Ann Oncol 2002; 235-45.
3. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170.
4. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - More than skin deep. J Clin Oncol 2005; In press.
5. Hay ED. An overview of the epithelio-mesenchymal transformation. Acta Anat 1995; 154:8-20.
6. Savagner P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. BioEssays 2001; 23:912-923.
7. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15:740-6.
8. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 2001; 105:425-31.
9. Bates RC, Mercurio AM. Tumor necrosis factor-α stimulates the epithelial to mesenchymal transition of human colonic organoids. Mol Biol Cell 2003; 14:1790-800.
10. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003; 13:1721-7.
11. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P. Mercurio AM. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115:339-47.
12. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002; 2:442-54.
13. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25.
14. Ruoslahti E. Integrins. J Clin Invest 1991; 87:1-5.
15. Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Crit Rev Oncol Hemat 2000; 36:61-74.
16. Busk M, Pytela R, Sheppard D. Characterization of the integrin αvβ6 as a fibronectin-binding protein. J Biol Chem 1992; 267:5790-6.
17. Yokosaki Y, Monis H, Chen J, Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem 1996; 271:24144-50.
18. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 1993; 41:1521-7.
19. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers D, Carpenter W, Gillett N, Sheppard D, Matthay MA, Albelda SM, Kramer RH, Pytela R. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995; 108:2241-51.
20. Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H. Expression of alpha(v)beta6 integrin in oral leukoplakia. Br J Cancer 2000; 82:1433-40.
21. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RCK. Tenascin and β6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002; 38:332-6.
22. Liotta L, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001; 411:375-9.
23. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166:2472-83.
24. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RH, Balmain A. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Diff 1998; 9:393-404.
25. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Downward J. Raf induces TGFβ production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000; 14:2610-22.
26. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a Rho-A-dependent mechanism. Mol Biol Cell 2001; 12:27-36.
27. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular-signal regulated kinase 2 activation. Cancer Res 2001; 61:4222-8.
28. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10:2462-77.
29. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Diff 1994; 5:267-75.
30. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor beta 1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999; 59:3379-86.
31. Oft M, Heider KH, Berg H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8:1243-52.
32. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, matthay MA, Rifkin DB, Sheppard D. The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96:319-28.
33. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
34. Ellis LM, Hoff PM. Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer. J Clin Oncol 2004; 22:1177-9.
35. Huber MA, Beug H, Wirth T. Epithelial-mesenchymal transition: NF-κB takes center stage. Cell Cycle 2004; 3:1477-80.